A phase I clinical trial is open testing AMG 176 in patients with relapsed or refractory multiple myeloma (as well as patients with acute myeloid leukemia). AMG 176 is an MCL-1 inhibitor (myeloid cell leukemia-1) that can prevent cancer cells from creating proteins to protect itself, and can cause cell death. The protein encoded by the MCL-1 gene belongs to the Bcl-2 family.
It is the first time this experimental drug is being given to humans. It is open-label, non-randomized, and will be available at multiple cancer centers across the country.
- Open-Label: Patients and their doctors will know both the treatment and the dose that they will be receiving.
- Dose Escalation: The amount of the study drug is periodically increased to determinethe maximum tolerated dose (MTD) to be used in future trials.
It is anticipated that 100 patients will join this study to explore dosing of AMG 176 (intravenously) in four different cohorts (or groups). Patients must have relapsed or refractory myeloma, with at least 2 lines of therapy, and satisfactory hematological function without transfusion or growth factor support.
Click here to learn more about this study and see if you may be eligible. You can also call SparkCures with any questions at (888) 828-2206.